
Sara Hurvitz, MD
Articles by Sara Hurvitz, MD


Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.

A look at the evolving role of neurooncologists in the treatment of patients with HER2+ breast cancer and brain metastases and future perspectives in the management of this patient population.

Experts have a conversation of the use of trastuzumab deruxtecan therapy for patients with progressive brain metastases while weighing common toxicities and clinical trial data.

Sara Hurvitz, MD, presents the case of a 66-year-old woman with ER+ HER2+ invasive ductal carcinoma and brain metastases.

A look at exciting clinical trials enrolling patients with HER2+ breast cancer and leptomeningeal disease, a previously unheard-of opportunity.

Oncologists debate the use of neratinib for metastatic HER2+ breast cancer treatment in the context of the HER2CLIMB clinical trial data on tucatinib.

Dr Stefania Maraka presents the case of a 53-year-old woman with de novo metastatic mutated ER/PR+ HER2+ breast cancer and brain metastases.

Experts discuss their choice of systemic therapies after a patient with metastatic HER2+ breast cancer and brain metastases progresses on tucatinib therapy.

Ruta Rao, MD, discusses her rationale for treating metastatic HER2+ breast cancer with a tucatinib-containing regimen based on data from the HER2CLIMB trial.

Stefania Maraka, MD, explains the second- and third-line treatment options for metastatic HER2+ breast cancer and how she collaborates with breast oncologists.

Dr Sara Hurvitz provides an overview of HER2+ breast cancer, and Dr Ruta Rao details the frontline treatment options available for metastatic cases.

Ruta Rao, MD, presents the case of a 36-year-old woman with metastatic HER2+ breast cancer and brain metastases.

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss clinical implications of a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, highlight key concepts from a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

CancerNetwork® spoke with Dr. Sara Hurvitz, associate professor of medicine at the University of California, Los Angeles, about therapy options for breast cancer.

During the 2018 Miami Breast Cancer Conference, Dr. Sara Hurvitz discussed current management options for patients with early-stage HER2-positive breast cancer.
Latest Updated Articles
Third-Line Treatment Data for HER2+ Advanced Breast CancerPublished: August 12th 2021 | Updated:
HER2+ Advanced Breast Cancer: Selecting Third-Line TherapyPublished: August 13th 2021 | Updated:
Management of Early-Stage HER2-Positive Breast CancerPublished: March 15th 2018 | Updated:
Dr. Hurvitz Discusses Therapy Options for Breast CancerPublished: October 17th 2019 | Updated:


